Tumor-Derived PGE2 Gives NK Cells a Headache.
| Autor: | Knudsen NH; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA., Manguso RT; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA. Electronic address: rmanguso@broadinstitute.org. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Immunity [Immunity] 2020 Dec 15; Vol. 53 (6), pp. 1131-1132. |
| DOI: | 10.1016/j.immuni.2020.11.018 |
| Abstrakt: | Tumors use active immunosuppressive mechanisms to evade immune recognition and shape the local inflammatory environment. In this issue of Immunity, Bonavita et al. report that tumor-derived PGE2 blocks early activation of natural killer cells and interferes with subsequent adaptive immune cell recruitment to the tumor. (Copyright © 2020 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|